2 papers in the library · 10 citations · publishing 2023-2026
ACS medicinal chemistry letters September 14, 2023 Marie Layzell, Peter Rands, Meghan Good et al. 6 citations
A deuterated analogue of DMT, called D2-DMT, has a longer half-life and slower clearance in liver cell fractions than standard DMT while maintaining a similar receptor binding profile, making it a promising candidate for extended treatment of major depressive disorder.
Nat Med February 16, 2026 David Erritzøe, Tommaso Barba, Tiffanie Benway et al. 4 citations
A single 21.5-mg intravenous dose of the psychedelic DMT, given with psychotherapeutic support, produced a rapid and significant reduction in depressive symptoms in adults with moderate-to-severe major depressive disorder. In a double-blind, placebo-controlled trial with 34 participants, those receiving DMT showed a greater decrease in depression scores at two weeks compared to placebo. Antidepressant effects persisted up to three months in an open-label phase. Adverse events were mostly mild to moderate, and no serious adverse events occurred.